GT BIOPHARMA, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
GT BIOPHARMA, INC. (GTBP) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $53.00 thousand for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2024-11-14
- GT BIOPHARMA, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- GT BIOPHARMA, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-06-30 was $27.00K, a 3.85% increase year-over-year.
- GT BIOPHARMA, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-03-31 was $26.00K, a 4.00% increase year-over-year.
- GT BIOPHARMA, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2023-12-31 was $34.00K, a 36.00% increase year-over-year.
- GT BIOPHARMA, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $112.00K, a 17.89% increase from fiscal 2022.
- GT BIOPHARMA, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $95.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $27.00K derived: sum of 2 quarters · filed 2024-11-14 | $53.00K 10-Q · filed 2024-11-14 | $87.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | $27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $53.00K 10-Q · filed 2024-08-14 | $87.00K derived: sum of 3 quarters · filed 2024-08-14 | $114.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-03-31 | $26.00K 10-Q · filed 2024-05-15 | $60.00K derived: sum of 2 quarters · filed 2024-05-15 | $87.00K derived: sum of 3 quarters · filed 2024-11-14 | $113.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-12-31 | $34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $61.00K derived: sum of 2 quarters · filed 2024-11-14 | $87.00K derived: sum of 3 quarters · filed 2024-11-14 | $112.00K 10-K · filed 2024-03-26 |
| 2023-09-30 | $27.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $53.00K derived: sum of 2 quarters · filed 2024-11-14 | $78.00K 10-Q · filed 2024-11-14 | $103.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $51.00K 10-Q · filed 2024-08-14 | $76.00K derived: sum of 3 quarters · filed 2024-08-14 | $100.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $25.00K 10-Q · filed 2024-05-15 | $50.00K derived: sum of 2 quarters · filed 2024-05-15 | $74.00K derived: sum of 3 quarters · filed 2024-05-15 | $97.00K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $49.00K derived: sum of 2 quarters · filed 2024-03-26 | $72.00K derived: sum of 3 quarters · filed 2024-03-26 | $95.00K 10-K · filed 2024-03-26 |
| 2022-09-30 | $24.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-31 | $47.00K derived: sum of 2 quarters · filed 2023-08-07 | $70.00K 10-Q · filed 2022-10-31 | |
| 2022-06-30 | $23.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $46.00K 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $23.00K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |